替比夫定(telbivudine)是美国食品药品管理局(FDA)批准的治疗慢性病毒性肝炎的新药。该药由诺华公司开发研制,于2006年10月在美国上市,商品名为Tyzeka,为口服片剂[1]。替比夫定是抑制乙肝病毒DNA聚合酶(逆转录酶)合成的腺苷核苷类似物,在细胞激酶的作用下被磷酸化为活性代谢产 Telbivudine is a new drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic viral hepatitis. Developed by Novartis, the drug is marketed in the United States in October 2006 under the trade name Tyzeka as an oral tablet [1]. Telbivudine is an adenosine nucleoside analog that inhibits the synthesis of hepatitis B virus DNA polymerase (reverse transcriptase) and is phosphorylated to an active metabolite under the action of a cellular kinase